These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32474203)

  • 21. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
    Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
    BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q; Ming WK; Yip WY; You JHS
    Int J Infect Dis; 2019 Jan; 78():44-49. PubMed ID: 30342251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease.
    Berende A; Nieuwenhuis L; Ter Hofstede HJM; Vos FJ; Vogelaar ML; Tromp M; van Middendorp H; Donders ART; Evers AWM; Kullberg BJ; Adang EMM
    PLoS One; 2018; 13(4):e0195260. PubMed ID: 29608590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.
    Ryckman TS; McQuaid CF; Cohen T; Menzies NA; Kendall EA
    Lancet Glob Health; 2024 Oct; 12(10):e1629-e1637. PubMed ID: 39159654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shortened Treatment Regimens for Drug Sensitive TB.
    Singhal KK; Shinde M
    Indian J Pediatr; 2024 Jul; 91(7):724-729. PubMed ID: 38100071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India.
    Muniyandi M; Karikalan N; Velayutham B; Rajsekar K; Padmapriyadarsini C
    Trop Med Infect Dis; 2022 Oct; 7(10):. PubMed ID: 36288029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India.
    Azman AS; Golub JE; Dowdy DW
    BMC Med; 2014 Oct; 12():216. PubMed ID: 25358459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area.
    Li J; Yip BHK; Leung C; Chung W; Kwok KO; Chan EYY; Yeoh E; Chung P
    PLoS One; 2018; 13(1):e0189531. PubMed ID: 29293514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Latent Tuberculosis Infection Testing Strategies for HIV-Positive Individuals in Hong Kong.
    Wong NS; Chan KCW; Wong BCK; Leung CC; Chan WK; Lin AWC; Lui GCY; Mitchell KM; Lee SS
    JAMA Netw Open; 2019 Sep; 2(9):e1910960. PubMed ID: 31490541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of isoniazid chemoprevention in close contacts.
    Diel R; Nienhaus A; Schaberg T
    Eur Respir J; 2005 Sep; 26(3):465-73. PubMed ID: 16135730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness.
    Arinaminpathy N; Nandi A; Vijayan S; Jha N; Nair SA; Kumta S; Dewan P; Rade K; Vadera B; Rao R; Sachdeva KS
    BMJ Glob Health; 2021 Oct; 6(10):. PubMed ID: 34610905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic review: tuberculosis.
    Houston S; Pozniak A; Ray CS
    Cent Afr J Med; 1991 Aug; 37(8):250-9. PubMed ID: 1807799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis.
    Macintyre CR; Plant AJ; Hendrie D
    Health Econ; 2000 Jul; 9(5):411-21. PubMed ID: 10903541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simplified cost-effectiveness model to guide decision-making for shortened anti-tuberculosis treatment regimens.
    Zwerling A; Gomez GB; Pennington J; Cobelens F; Vassall A; Dowdy DW
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):257-60. PubMed ID: 26792481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
    Azadi M; Bishai DM; Dowdy DW; Moulton LH; Cavalcante S; Saraceni V; Pacheco AG; Cohn S; Chaisson RE; Durovni B; Golub JE
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1443-8. PubMed ID: 25517809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens.
    Gospodarevskaya E; Tulloch O; Bunga C; Ferdous S; Jonas A; Islam S; Rahman M; Hussain MA; Haque MN; Egwaga S; Gardiner E; PrayGod G; Islam MA; Mann GH; Wells WA; Squire SB
    Int J Tuberc Lung Dis; 2014 Jul; 18(7):810-7. PubMed ID: 24902557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.